New non-hormonal therapies have been traditionally evaluated in hormone refractory disease, but none are effective when used in this end-stage setting. A more rational strategy would apply novel agents earlier in order to delay or prevent the emergence of the AI phenotype. The identi®cation of genes expressed during AI progression must be followed by an investigation of their functional signi®cance in this process. Genes that demonstrate a causative role in hormone independence can then be targeted for therapeutic intervention.
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The LNCaP and Shionogi tumour models are reproducible systems which mimic androgen-independent progression and are useful for studying mechanisms of and therapeutic targeting against AI progression. We use comparative hybridization of high-density cDNA arrays to characterize changes in hundreds of genes, some of which become differentially expressed during AI progression of LNCaP and Shionogi tumours. Genes which are altered in expression between these two states are further characterized by Northern analysis during multiple points in the progression pathway. In general, androgen withdrawal results in an upregulation of at least 20 genes in the Shionogi or LNCaP tumour models, resulting in the emergence of an androgen-repressed pattern of gene expression. Many genes become upregulated early (within days) of androgen withdrawal associated with tumour cell apoptosis (e.g. TRPM-2, cathepsins, Bcl-2, BclxL and various IGFBPs).
Targeting genes upregulated by androgen withdrawal may increase the extent of castration-induced apoptosis, thereby prolonging the time to overt recurrence. The Bcl-2 proto-oncogene belongs to a family of related genes whose proteins regulate a ®nal common pathway regulating programmed cell death in normal and abnormal cell populations. Virtually all hormone refractory prostate carcinomas express Bcl-2, supporting the hypothesis that Bcl-2 expression confers resistance to androgen withdrawal by cells blocking the usual apoptotic signal from androgen manipulation. Induction of apoptotic cell death after androgen ablation may be enhanced through functional inhibition of Bcl-2 and serve as a rational basis for delaying progression to androgen independence and enhancing chemosensitivity in prostate cancer.
Method and results
We used the LNCaP and Shionogi tumour models to test whether adjuvant use of Bcl-2 antisense oligodeoxynucleotides (AS-ODNs) with androgen ablation or taxanes delayed AI progression. Bcl-2 expression is upregulated following castration in both model systems in vivo. Bcl-2 AS-ODNs induced sequence-speci®c reduction in Bcl-2 mRNA and protein levels in LNCaP or Shionogi cells in vitro, and inhibited tumour growth and serum PSA increases in mice after castration. Time to CR postcastration was accelerated and time to AI recurrence signi®cantly prolonged. Bcl-2 AS-ODNs also enhanced chemosensitivity in both tumour model systems. Paclitaxel treatment induced Bcl-2 phosphorylation and consequently inhibited the formation of Bcl-2/Bax heterodimer formation in a dose-dependent manner. Shionogi tumour cell growth in vitro was not altered by either 500 nM antisense Bcl-2 ODN or 10 nM taxol alone, but the combined treatment of 500 nM antisense Bcl-2 ODN and 10 nM taxol reduced the IC50 of taxol from 100 to 10 nM. Characteristic apoptotic DNA laddering and cleavage of PARP were demonstrated only after the combined treatment. Adjuvant in vivo administration of antisense Bcl-2 ODN and polymeric micellar taxol following castration resulted in a signi®cant delay in the emergence of AI recurrent tumours compared with the administration of either agent alone. Furthermore, combined treatment of mice bearing AI recurrent Shionogi tumours with antisense Bcl-2 ODN and micellar taxol signi®cantly inhibited the tumour growth compared with treatment with either agent alone.
Conclusion
These ®ndings suggest that downregulation of Bcl-2 by antisense ODN chemosensitises AI Shionogi tumours to paclitaxel over and above the effects of paclitaxel-induced phosphorylation of Bcl-2. Clinical studies using Bcl-2 ASODNs alone or in combination with mitoxanthrone in prostate cancer are now underway at our institution. Preliminary data targeting additional anti-apoptotic genes will also be presented.
